Satiation peptides for weight loss and altered taste sensitivity
AssigneeUniversity of Florida Research Foundation, Inc.
InventorsSergei Zolotukhin, Sean M. Crosson, Cedrick Shawn Dotson, Seth Currlin, Andres Acosta
Life of this patent
Estimating the term…
Abstract
The present application provides methods and compositions for AAV-mediated delivery of PYY and Glucagon-like Peptide 1 or an analog thereof (e.g., Exendin-4) to a subject (e.g., the saliva of a subject). In some embodiments, compositions and methods for topical delivery of Ex-4 and PYY peptides also are provided. Methods and compositions are useful to promote weight loss and/or altered lipid taste sensitivity, as well as for the treatment of diabetes.
Claims18
A method of inducing satiation in a subject comprising administering a recombinant Adeno-associated viral (rAAV) vector comprising an expression cassette that comprises a polynucleotide sequence that encodes a PYY peptide and a Glucagon-like Peptide 1 (GLP-1) analog to the submandibular salivary gland of the subject, wherein the rAAV vector transduces submandibular salivary gland cells, wherein the GLP-1 analog is Exendin-4 (Ex-4) peptide, wherein satiation is observed in the subject more than eight weeks after administration.
A method of increasing satiation gut peptide concentration in the saliva of a subject, the method comprising administering a rAAV vector comprising an expression cassette that comprises a polynucleotide sequence that encodes a PYY peptide and a Glucagon-like Peptide 1 (GLP-1) analog to the submandibular salivary gland of the subject, wherein the rAAV vector transduces submandibular salivary gland cells, wherein the GLP-1 analog is Exendin-4 (Ex-4) peptide, and wherein an increased satiation gut peptide concentration is observed in the subject more than eight weeks after administration.
Dependencies are inferred from the claim text.